BioCentury | Jan 4, 2018
Distillery Therapeutics

Ophthalmic disease

...caused by mutations in RPE65, LRAT or MERTK. TARGET/MARKER/PATHWAY: Retinal pigment epithelium-specific protein 65kDa (RPE65); lecithin retinol acyltransferase...
...cmonville@istem.fr Chris Lieu Institut National de la Sante et de la Recherche Medicale (INSERM) c-Mer proto-oncogene tyrosine kinase (MERTK) Lecithin retinol acyltransferase...
BioCentury | Dec 21, 2017
Preclinical News

Researchers develop hESC-derived RPE cell sheet

...RPE cell sheets to treat retinitis pigmentosa caused by mutations in RPE-specific protein 65kDa (RPE65), lecithin retinol acyltransferase...
BioCentury | Mar 3, 2014
Clinical News

QLT091001: Preliminary Phase Ib data

Preliminary data from in open-label, international Phase Ib trial in 27 patients with LCA or RP due to inherited lecithin-retinol acyltransferase (LRAT) or retinal pigment epithelium-specific protein 65kDa (RPE65) gene mutations showed that 10, 40...
BioCentury | May 28, 2012
Company News

QLT ophthalmic, drug delivery news

QLT postponed its annual meeting to June 4 from May 24 after shareholders controlling about 22.8 million, or about 40%, of the company's shares submitted proxy statements to the SEC in support of a dissident...
BioCentury | Mar 12, 2012
Clinical News

QLT091001: Preliminary Phase Ib data

Preliminary data from an open-label Phase Ib trial in 17 patients with RP due to inherited lecithin-retinol acyltransferase (LRAT) or retinal pigment epithelium-specific protein 65kDa (RPE65) gene mutations showed that once-daily 40 mg/m 2 QLT091001...
BioCentury | May 9, 2011
Clinical News

QLT091001: Phase Ib data

Interim data from 12 patients in an open-label, Canadian Phase Ib trial showed that QLT091001 resulted in clinically meaningful improvement in visual field and/or visual acuity in 8 patients. Visual field was significantly improved by...
BioCentury | Nov 8, 2010
Clinical News

QLT091001: Phase Ib amended

QLT amended an ongoing, open-label, Canadian Phase Ib trial of QLT091001 to include patients with retinitis pigmentosa (RP) and subsequently increased enrollment to up to 24 from up to 8. The trial, which has already...
BioCentury | May 3, 2010
Clinical News

QLT091001: Interim Phase Ib data

Interim data from 3 patients ages 10, 12 and 38 years old with inherited lecithin-retinol acyltransferase (LRAT) gene mutations in an ongoing, open-label, Canadian Phase Ib trial showed that once-daily oral QLT091001 for 7 days...
BioCentury | Dec 21, 2009
Clinical News

QLT091001: Phase Ib started

QLT began an open-label, Canadian Phase Ib trial to evaluate oral QLT091001 given once daily for 7 days in 8 pediatric patients with inherited deficiency of retinal pigment epithelium protein 65 (RPE65) or lecithin-retinol acyltransferase...
Items per page:
1 - 9 of 9